2020-2026年医药及生物技术领域早期药物研发（EDR）合作条款及协议

本报告基于数据，全面分析了企业签订EDR合作协议的背景和原因，以及支撑这些协议的财务和策略条件。作为业界必备的参考资料，本报告深入剖析了医药和生物技术领域EDR合作的结构、谈判动态和财务考量。

EDR授权协议通常授予被授权人进一步开发授权人产品或技术的权利或选择权。这些协议通常包含多个组成部分，可能从联合研发开始，逐步发展到商业化协议。

本报告详细分析了医疗保健领域最新的EDR协议，帮助企业了解市场趋势、评估竞争对手的协议结构并优化自身的谈判策略。

生技与製药业交易撮合者必备的资源

本报告是参与生物製药交易的业务拓展、法律和财务专业人士不可或缺的资讯来源。

凭藉全面的洞察、庞大的合约资料库以及对合约文件的直接访问，本报告是以下用途的终极工具：

• 交易结构与财务条款基准分析
• 优化谈判策略
• 评估潜在合作伙伴的弹性和交易行为
• 识别早期药物研发合作的趋势和最佳实践
• 对于那些正在努力建立早期药物研发合作关係的人士而言，本报告提供了必要的清晰度、数据和策略指导，以确保与合适的合作伙伴达成高价值协议。
• 为何本报告对交易撮合者至关重要
• 深入了解潜在合作伙伴的弹性和谈判策略，对于成功建构早期药物研发交易至关重要。 虽然主要财务条款（例如，预付款、里程碑付款、特许权使用费）提供了一个概览，但合约文件能够更深入地揭示这些付款的实际触发条件和条件。这些关键细节往往在新闻稿和传统资料库中被忽略。
• 本报告全面涵盖了自 2020 年以来发布的所有早期药物研发合作协议，并包含了可用的财务条款。此外，报告还提供了 2,562 个链接，指向详细的线上合约记录，包括已向美国证券交易委员会 (SEC) 提交的公开合约文件。
• 分析这些协议能够帮助企业建立符合产业基准的交易结构，并透过最大化潜在收益来获得竞争优势。
• 药物研发早期阶段合作趋势的综合分析

目录

摘要整理

第一章：引言

第二章：企业为何在药物研发早期阶段开展合作

• 合作在药物研发早期阶段的作用
  • 药物研发早期阶段的引进许可
  • 药物研发早期阶段的对外许可
• 药物研发早期阶段、临床前阶段及临床阶段交易的差异
• 在药物研发早期阶段达成合作协议的原因
  • 授权人参与早期阶段合作的原因交易
  • 被授权人参与早期交易的原因
• 药物研发早期阶段合作协议的未来

第三章 早期药物研发交易策略与架构

• 公司在哪个阶段开展合作？
  • 製药/生技领域的早期合作
  • 製药/生技领域的后期合作
• 早期与后期合作－风险与成本比较
• 公司在早期、临床前和临床阶段的合作上分别投入多少资金？
• 纯许可和多组分合作协议
• 纯许可协议结构
  • 纯许可协议范例
  • 个案研究
• 多组分药物研发早期合作协议
  • 多组分早期条款范例
  • 个案研究

第四章 早期药物研发合作：支付策略

• 早期药物研发支付策略
• 付款方式
  • 标题
  • 预付款
  • 贷款
  • 转换贷款
  • 公平性
  • 研发资金
  • 许可费
  • 里程碑付款
  • 特许权使用费付款方式
  • Quids（权益）
  • 选择权付款

第五章：早期药物研发交易趋势

• 早期药物研发合作：依交易类型划分
• 早期药物研发合作：依疾病划分
• 早期药物研发合作：依技术类型划分
• 早期药物研发合作：2020 年至 2026 年最活跃的公司

第六章：早期药物研发合作中的付款条款

• 早期药物研发付款条款指南
  • 预付款
  • 里程碑付款
  • 特许权使用费
• 早期药物研发合作中的付款条款探讨：交易资料分析
  • 公开数据
  • 调查数据
• 付款条款分析
  • 要点
  • 预付款
  • 里程碑付款
  • 特许权使用费率

第七章：早期药物研发合作协议概况

• 早期药物研发合作协议概况：依金额排序

第八章：早期药物研发合作最活跃的25家公司

• 早期药物研发合作最活跃的25家公司

第九章：早期药物研发合作计画目录

• 早期药物研发合作2020 年至 2026 年的合作关係

第十章：早期药物研发合作：依研发阶段划分

• 早期药物研发合作

附录

• 附录 1 - 学术机构与非营利组织合作：依公司（A-Z）划分
• 附录 2 - 学术机构与非营利组织合作：依产业划分
• 附录 3 - 学术机构与非营利组织合作：依研发阶段划分
• 附录 4 - 学术机构与非营利组织合作：依治疗领域划分
• 附录 5 - 学术机构与非营利组织合作：依技术划分
• 生物製药研究股份有限公司
• 当前合作关係
• 当前协议
• 近期关于当前合作关係的报告标题合作

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2026)

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2026) report offers a comprehensive, data-driven analysis of how and why companies engage in discovery-stage partnering deals and the financial and strategic terms underpinning these agreements. This essential industry resource provides deep insights into the structure, negotiation dynamics, and financial considerations that define early-stage partnerships in the pharmaceutical and biotech sectors.

At the discovery stage, licensing agreements typically grant the licensee rights or options to further develop a licensor's product or technology. These agreements are often multi-component, beginning with collaborative research and development (R&D) and potentially leading to commercialization agreements.

This report provides a detailed breakdown of the latest discovery-stage agreements in the healthcare sector, helping companies identify market trends, evaluate competitive deal structures, and optimize their own negotiation strategies.

A Must-Have Resource for Biotech and Pharma Dealmakers

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report is an indispensable resource for business development, legal, and financial professionals involved in biopharma dealmaking.

With comprehensive insights, a vast deal database, and direct access to contract documents, this report serves as the ultimate tool for:

• Benchmarking deal structures and financial terms
• Optimizing negotiation strategies
• Assessing potential partners' flexibility and deal-making behavior
• Identifying trends and best practices in discovery-stage partnerships
• For those looking to navigate the complex landscape of discovery-stage partnering, this report offers the clarity, data, and strategic guidance needed to secure high-value agreements with the right partners.
• Why This Report is Essential for Dealmakers
• Gaining insight into the flexibility and negotiation strategies of potential partners is crucial in structuring a successful discovery-stage deal. While headline financial terms (e.g., upfront payments, milestones, and royalties) provide a broad overview, contract documents offer a deeper understanding of the actual triggers and conditions for these payments-critical details that press releases and traditional databases often omit.
• This report contains a comprehensive listing of all discovery-stage partnering deals announced since 2020, including financial terms where available. It also features 2,562 links to detailed online deal records, including publicly available contract documents filed with the SEC.
• By analyzing these agreements, companies gain a competitive edge in structuring deals that align with industry benchmarks while maximizing potential returns.
• Comprehensive Analysis of Discovery-Stage Partnering Trends

The first chapters of the report provide a detailed orientation to discovery-stage deal-making and strategic considerations:

Chapter 1 - Introduction to the report

Chapter 2 - Why companies engage in discovery-stage partnerships

Chapter 3 - Strategic approaches and deal structures, with case studies

Chapter 4 - Payment strategies, including upfronts, milestones, and royalties

Chapter 5 - Discovery-stage deal-making analysis categorized by year, therapeutic area, technology type, and key dealmakers

Chapter 6 - Detailed analysis of financial terms, including headline values, upfront payments, milestone triggers, and royalty rates

Chapter 7 - A review of the leading discovery-stage deals by headline value

Chapter 8 - The top 25 most active discovery-stage dealmakers

Chapter 9 - A database of discovery-stage partnering agreements, including contract documents where available

Chapter 10 - A comprehensive directory of all discovery-stage deals announced since 2020

• Each deal record is linked to Current Agreements, a proprietary database that provides easy access to full deal structures, financial terms, and contract documents.
• Key Benefits of the Report
• Comprehensive insights into discovery-stage deal trends since 2020
• Access to key financial terms, including headline values, upfronts, milestones, and royalty structures
• Breakdown of deal structures, with real-world case studies
• Analysis of contractual terms, including real-world clause examples
• Benchmarking of deal terms based on actual agreements
• Due diligence insights to assess the suitability of proposed deal terms for potential partners
• Scope of the Report

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides:

• Analysis of discovery-stage dealmaking trends in the biopharma industry since 2020
• Insight into financial structures, including upfront, milestone, and royalty payments
• Case studies of real-life discovery-stage agreements
• Access to over 2,690 discovery-stage deals, with contract records where available
• Profiles of the most active discovery-stage dealmakers
• Detailed analysis of the highest-value discovery-stage deals

Each deal record is indexed by:

• Company (A-Z)
• Headline value
• Stage of development at signing
• Deal type
• Specific therapy focus
• For easy access, every deal record links to an online version, and where available, the full contract document.
• Critical Questions Answered

By analyzing actual contract agreements where available, this report provides definitive answers to critical questions such as:

• What specific rights are granted in each agreement?
• What exclusivity terms apply?
• How is the deal structured financially? (Upfronts, milestones, royalties)
• How are sales and payments audited?
• Who controls development, manufacturing, and commercialization?
• How is intellectual property handled?
• How are confidentiality and publication rights managed?
• Under what conditions can a deal be terminated?
• What dispute resolution mechanisms are in place?
• What happens in the event of a change in ownership?
• Gain the competitive edge-explore the report today.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner at discovery stage?

• 2.1. Introduction
• 2.2. The role of discovery stage partnering
  • 2.2.1. In-licensing at discovery stage
  • 2.2.2. Out-licensing at discovery stage
• 2.3. Difference between discovery, preclinical and clinical stage deals
• 2.4. Reasons for entering into discovery stage partnering deals
  • 2.4.1. Licensors reasons for entering discovery stage deals
  • 2.4.2. Licensees reasons for entering discovery stage deals
• 2.5. The future of discovery stage partnering deals

Chapter 3 - Discovery stage deal strategies and structure

• 3.1. Introduction
• 3.2. At what stage do companies partner?
  • 3.2.1. Partnering early in pharmaceutical/biotech
  • 3.2.1.1. Discovery and preclinical stage partnering case studies
  • 3.2.1.1.a. Case study 1
  • 3.2.1.1.b. Case study 2
  • 3.2.1.1.c. Case study 3
  • 3.2.1.1.d. Case study 4
  • 3.2.2. Partnering later in pharmaceutical/biotech
  • 3.2.2.1. Clinical stage partnering case studies
  • 3.2.2.1.a. Case study 5
  • 3.2.2.1.b. Case study 6
  • 3.2.2.1.c. Case study 7
  • 3.2.2.1.d. Case study 8
• 3.3. Early and later stage partnering - a risk/cost comparison
• 3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
• 3.5. Pure versus multi-component partnering deals
• 3.6. Pure licensing agreement structure
  • 3.6.1. Example pure licensing agreements
  • 3.6.1.a. Case study 9
  • 3.6.1.b. Case study 10
• 3.7. Multicomponent discovery stage partnering agreements
  • 3.7.1.a. Example multicomponent early stage clauses
  • 3.7.1.a. Case study 11
  • 3.7.1.b. Case study 12

Chapter 4 - Discovery stage partnering payment strategies

• 4.1. Introduction
• 4.2. Discovery stage payment strategies
• 4.3. Payment options
  • 4.3.1. Headline values
  • 4.3.2. Upfront payments
  • 4.3.2.1. Conditionality of upfront payments
  • 4.3.3. Loans
  • 4.3.4. Convertible loans
  • 4.3.5. Equity
  • 4.3.6. R&D funding
  • 4.3.7. Licensing fees
  • 4.3.8. Milestone payments
  • 4.3.9. Royalty payments
  • 4.3.9.1. Issues affecting royalty rates
  • 4.3.9.2. Royalties on combination products
  • 4.3.9.2.a. Case study 13
  • 4.3.9.3. Guaranteed minimum/maximum annual payments
  • 4.3.9.4. Royalty stacking
  • 4.3.9.5. Royalties and supply/purchase contracts
  • 4.3.10. Quids
  • 4.3.11. Option payments

Chapter 5 - Trends in discovery stage deal making

• 5.1. Introduction
• 5.2. Discovery stage partnering over the years
  • 5.2.1. Attributes of discovery deals
• 5.3. Discovery stage partnering by deal type
• 5.4. Discovery stage partnering by disease type
• 5.5. Partnering by discovery stage technology type
• 5.6. Discovery stage partnering by most active company, 2020 to 2026

Chapter 6 - Payment terms for discovery stage partnering

• 6.1. Introduction
• 6.2. Guidelines for discovery stage payment terms
  • 6.2.1. Upfront payments
  • 6.2.2. Milestone payments
  • 6.2.3. Royalty payments
• 6.3. Discovery stage payment terms - deal data analysis
  • 6.3.1. Public data
  • 6.3.2. Survey data
• 6.4. Payment terms analysis
  • 6.4.1. Discovery stage headline values
  • 6.4.2. Discovery stage deal upfront payments
  • 6.4.3. Discovery stage deal milestone payments
  • 6.4.4. Discovery stage royalty rates

Chapter 7 - Leading discovery stage deals

• 7.1. Introduction
• 7.2. Top discovery stage deals by value

Chapter 8 - Top 25 most active discovery stage dealmakers

• 8.1. Introduction
• 8.2. Top 25 most active discovery stage dealmakers

Chapter 9 - Discovery stage partnering contracts directory

• 9.1. Introduction
• 9.2. Discovery stage deals with contracts 2020 to 2026

Chapter 10 - Discovery stage deal making by development stage

• 10.1. Introduction
• 10.2. Deals by discovery stage

Appendices

• Appendix 1 - Discovery stage dealmaking by companies A-Z
• Appendix 2 - Discovery stage dealmaking by industry sector
• Appendix 3 - Discovery stage dealmaking by stage of development
• Appendix 4 - Discovery stage dealmaking by therapy area
• Appendix 5 - Discovery stage dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
• Figure 3: Components of the pure licensing deal structure
• Figure 4: Payment options for discovery stage partnering deals
• Figure 5: Issues affecting royalty rates
• Figure 6: Discovery stage partnering frequency
• Figure 7: Discovery stage partnering by deal type
• Figure 8: Discovery stage partnering by disease type
• Figure 9: Discovery stage partnering by technology type
• Figure 10: Top 25 most active discovery stage dealmakers
• Figure 11: Review of median upfront payments for discovery stage deals
• Figure 12: Review of median milestone payments for discovery stage deals
• Figure 13: Review of median royalty payments for discovery stage deals
• Figure 14: Discovery stage deals with a headline value
• Figure 15: Discovery stage deals with an upfront value
• Figure 16: Discovery stage deals with a milestone value
• Figure 17: Discovery stage deals with a royalty rate value
• Figure 18: Top discovery stage deals by deal value
• Figure 19: Most active discovery stage dealmakers